Full-Time

Executive Director

Lifecycle Leader

Iovance Biotherapeutics

Iovance Biotherapeutics

501-1,000 employees

TIL-based T-cell therapies for solid tumors

Compensation Overview

$290k - $330k/yr

Remote in USA

Remote

Bachelor's, MBA, PhD, MD

Category
Business & Strategy (1)
Required Skills
Risk Management
Data Analysis

Get referred to Iovance Biotherapeutics

See people who can refer or advise you

Requirements
  • Bachelor's degree in a scientific discipline; advanced or professional degree highly desirable (e.g., PhD, MD, or MBA).
  • 15+ years of bio-pharmaceutical industry experience with at least 5 years of relevant work experiences in the biotech/pharmaceutical industry as a Lifecycle Leader or Program Team Leader.
  • Must demonstrate strong knowledge of the overall drug development process relevant to biotech/pharmaceutical companies; commercial launch experience and a depth of experience with drug development is required.
  • Experience working with or on program strategy teams required.
Responsibilities
  • The LCL is responsible for shaping the program's cross-functional vision, strategic context, and lifecycle plan (LCP) for both current and future business opportunities.
  • The LCL, in partnership with the Program Manager, will work with leadership & SMEs to build out appropriate internal ways of working to enable best practices around development of data driven recommendations, decision making and communication.
  • As the single point of accountability in a cross-functional team, the LCL ensures timely delivery and manages the associated execution plan and milestones, closely aligning them with the approved LCP.
  • The LCL oversees integration across Iovance involving multiple stakeholders to ensure optimal program execution in line with program strategy and LCP.
  • Collaborating with functional team leaders, the LCL fosters alignment across the different sub -teams to ensure execution will achieve team and corporate goals (Commercial Team, Development Team, Regulatory Team etc.)
  • Serving as a point of triage, the LCL facilitates clear decision-making by incorporating cross-functional input to address high-impact issues. This involves co-creating solutions to complex challenges in real time.
  • The LCL leads the team in framing program needs and develops a range of options and recommendations for presentation to the Executive Leadership Team (ELT). The LCL ensures transparent communication with senior leadership, highlighting relevant scenarios, assumptions, and risks to inform decision-making and trade-offs. The LCL also represents the enterprise mindset and ensures all relevant functional perspectives have been considered.
  • The LCL ensures the inclusion of subject matter experts (SMEs) and situational members in discussions, guided by a predefined agenda set with guidance from the Program Manager.
  • The LCL is accountable to the ELT for program recommendations and frames them within the context of the broader portfolio.
  • The LCL is accountable for day-to-day management of the program to ensure all established deliverables with high program impact remain on track and in line with program strategy.
  • The LCL is responsible for ensuring the health of the team, creating a highly functional environment with collaborative ways of working where debate and honest feedback are encouraged
  • Other responsibilities to consider: Risk identification and mitigation planning; ensuring financial stewardship of approved and recommended projects; clear communication throughout organization of key milestones, deliverables and progress; ensure appropriate resourcing of functions to achieve program goals and vision.
  • May work with Development and Commercial Teams to define the disease area strategy and to execute a business plan with clear deliverables and resource needs. This includes defining priorities and an approach to leveraging external opportunities in close collaboration with Business Development and academic experts.
  • Advocates on behalf of Iovance and effectively communicates scientific/medical/clinical concepts in both written and oral communication to both internal and external stakeholders.
  • Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics.
  • Perform miscellaneous duties as assigned.
Desired Qualifications
  • Strong leadership skills from leading cross-functional teams in a matrix organization, with highly collaborative instincts and a track record of resolving conflicts within the team.
  • Ability to communicate clearly and effectively with clinical scientists, biologists, manufacturing experts, as well as with regulatory and commercial colleagues at all levels of the organization.
  • High degree of organizational awareness and understanding of change management and leading innovation.
  • Possess significant depth and breadth of experience across phases of drug development that enable you to immediately bring considerable strategic value to a project.
  • Possess understanding of drug development experience and understand what it takes to shepherd an asset through its lifecycle.
Iovance Biotherapeutics

Iovance Biotherapeutics

View

Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2007

Get referred to Iovance Biotherapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $99.3 million, up 66%, with 56% gross margin.
  • More than 95 ATCs are active, and management targets 110 by year-end 2026.
  • FDA Fast Track for lifileucel in soft tissue sarcoma expands the pipeline beyond melanoma.

What critics are saying

  • The 2025 class-action litigation alleges misleading guidance and commercialization claims; discovery runs through 2026.
  • Iovance cut nearly 20% of staff in 2025 to extend runway after weak Amtagvi adoption.
  • If ATC scaling stalls or reimbursement slips, Amtagvi stays niche and the cash runway breaks.

What makes Iovance Biotherapeutics unique

  • Amtagvi is the first FDA-approved TIL therapy, now approved in Australia, Canada, and the U.S.
  • Iovance controls iCTC manufacturing, shortening supply chain dependence for personalized cell therapy.
  • Over 400 granted patents and 1,000 pending applications protect TIL methods through 2042.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

1%
Yahoo Finance
Aug 13th, 2026
Iovance reports record Q2 2026 revenue of $99.3M, exceeding guidance

Iovance Biotherapeutics reported record financial results for the second quarter of 2026, with revenue of $99.3 million driven by strong demand for its TIL therapy Amtagvi. The company significantly exceeded both its Amtagvi and total revenue guidance for the quarter. Interim CEO Frederick Vogt highlighted the company's commercial progress, noting increased activity at authorised treatment centres, which are activating, enrolling, and infusing more patients than previously. The quarter also saw advances in the company's pipeline and new regulatory approvals and designations. Iovance positions itself as the global leader in developing and delivering tumour-infiltrating lymphocyte therapy for solid tumours. The company reported improved margins alongside the revenue growth during what it described as its strongest quarter to date.

Yahoo Finance
Aug 6th, 2026
Iovance shares surge 34% on record Q2 revenue of $99.3M, fuelling buyout speculation

Iovance Biotherapeutics' shares surged 34% on Thursday, heading for their best day since March 2020, after the biotech firm reported record second-quarter revenue that beat Wall Street expectations. Total product revenue rose 66% year over year to $99.3 million, topping analysts' estimates of $87.8 million. The company reported a loss of $0.11 per share, narrower than the expected $0.13 loss. US sales of Amtagvi, Iovance's cell therapy for advanced melanoma, were around $91 million. Interim president and CEO Frederick Vogt said the strong performance has prompted the company to review its previously issued 2026 revenue guidance of $350 million to $370 million. Iovance expects its cash in hand to fund operations through the second half of 2028.

Timothy Sykes
Aug 6th, 2026
Iovance Biotherapeutics stock grants signal post-amtagvi expansion.

Iovance Biotherapeutics stock grants signal post-amtagvi expansion. ELLIS HOBBS - UPDATED AUG. 6, 2026, 9:19 AM ET Iovance Biotherapeutics Inc. stocks have been trading up by 31.57 percent following highly positive sentiment around its latest trial progress. Key takeaways. * Iovance Biotherapeutics granted inducement stock options for 139,930 shares to 17 new non-executive hires under its 2021 Inducement Plan. * The options are priced at $4.66 per share and vest over three years, tying new talent to IOVA's long-term performance. * The hiring wave and equity grants follow the launch of FDA-approved TIL therapy Amtagvi, signaling that IOVA is building out its commercial engine. Live Update At 09:18:51 EDT: On Thursday, August 06, 2026 Iovance Biotherapeutics Inc. stock [NASDAQ: IOVA] is trending up by 31.57%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. IOVA sits in classic high-growth biotech territory: real revenue, heavy losses, and a big cash cushion. For active traders, that mix creates volatility and opportunity. The latest numbers show Iovance Biotherapeutics pulled in about $71.4M in quarterly revenue, with annualized revenue around $263.5M. That's not small for a company transitioning from development to commercialization. But the costs of rolling out Amtagvi are steep. Total quarterly expenses hit roughly $152.5M, leading to a net loss near $79M and an EBITDA of about -$69.3M. Profit margins look ugly on paper, with EBIT margin deeply negative, which is normal for a launch-phase biotech like IOVA. On the balance sheet, Iovance Biotherapeutics reports about $313.4M in cash and short-term investments and working capital over $337M. Debt is low, with total debt to equity at just 0.07 and a current ratio of 3.6, giving IOVA room to keep funding commercial build-out and R&D. For traders, that combination - rising revenue, heavy but funded losses, and low leverage - keeps IOVA squarely in the high-risk, high-reward camp. Why traders are watching IOVA's expansion moves. The latest catalyst for IOVA is not a trial headline or an FDA decision. It's a hiring signal. Iovance Biotherapeutics granted inducement stock options for 139,930 shares to 17 new non-executive hires, under its 2021 Inducement Plan, at an exercise price of $4.66, vesting over three years. That sounds routine, but traders should read between the lines. You don't stack your team and hand out equity if you're preparing to shrink. IOVA is clearly staffing up after bringing its FDA-approved TIL therapy, Amtagvi, to market. Those new hires are likely tied to commercial operations, manufacturing scale-up, and support functions that turn science into recurring revenue. The three-year vesting schedule tells you management wants these people locked in for the long haul. There is a modest dilutive angle. Another 139,930 shares on top of roughly 446M outstanding is a tiny percentage, but it's still new paper. For short-term traders, it rarely moves the needle by itself. For swing traders and position traders in IOVA, the key takeaway is management confidence: Iovance Biotherapeutics is acting like a company expecting Amtagvi demand to ramp. Overlay that with the chart. Daily data show IOVA slipping from the mid-$5s to the low $4s, a clear pullback after prior momentum. Intraday, though, the 5-minute tape shows a strong premarket push from around $4.30 up toward $5.70, with a series of higher lows. That's classic early accumulation behavior around a news-supported story. When fundamentals show expansion and the tape shows renewed buying, traders pay attention. Conclusion. Iovance Biotherapeutics is still burning cash, but the story has shifted from "will they get a product approved" to "how big can this commercial rollout get." The inducement stock options for 17 new non-executive hires are a tell. IOVA is building the infrastructure to support Amtagvi and push TIL therapy deeper into the oncology market. Management is trading cash and shares today for potential scale and pricing power tomorrow. For short-term traders, IOVA's recent slide from about $5.50 into the low $4 range created a dip that is now being tested by aggressive premarket buyers. Volatility is high, liquidity is there, and headlines around expansion and hiring give the crowd a clear narrative to trade. For longer-term, research-focused traders, the balance sheet strength and low leverage give Iovance Biotherapeutics room to execute without immediate financing pressure, even as margins stay sharply negative. As Tim Sykes likes to remind traders, "Patterns repeat, but only for those who study them and stay disciplined." That discipline also includes emotional resilience and learning from every trade - wins and losses. As millionaire penny stock trader and teacher Tim Sykes, says, "Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.". IOVA is another biotech where that mindset applies. Study the chart, understand the cash runway, track how Amtagvi sales trend, and always remember this is education and research - not a buy or sell call. Traders who respect the risk and react to the price action, not the hype, will be in the best position to capitalize on whatever Iovance Biotherapeutics does next. This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: One-of-a-kind AI play revealed. If you'd put $2,000 into Nvidia back in 2020, you'd be sitting on more than $30,000 today. The stock's been an absolute monster... But if you think you missed the boat, then you need to see this urgent message TODAY. Because not only am I revealing why the REAL AI boom is only just getting started... I'm also going to show you my top AI recommendation that's been CRUSHING it in this market. It has nothing to do with Nvidia... or Meta... or OpenAI... or anything else you're probably thinking. It's a unique AI play I'm certain you're not hearing from anyone else... One that could give you the chance to target an entire YEAR of peak Nvidia potential... In just one day. How much has this post helped you? (0 votes, average: 0 out of 5)

StocksToTrade
Aug 6th, 2026
IOVA stock grants signal aggressive post-amtagvi expansion.

IOVA stock grants signal aggressive post-amtagvi expansion. TIM BOHEN - UPDATED AUG. 6, 2026, 9:17 AM ET Iovance Biotherapeutics Inc. stocks have been trading up by 32.95 percent amid heightened optimism around its novel cancer therapies. Key takeaways. * Inducement stock options for 139,930 shares were granted to 17 new non-executive hires under Iovance's 2021 Inducement Plan. * Options carry a $4.66 strike price and vest over three years, rewarding long-term execution rather than quick wins. * The grants follow the FDA launch of Iovance's TIL therapy Amtagvi, signaling ongoing hiring and commercial build-out. * Active traders are watching IOVA as management leans into growth while the stock trades in the mid-single digits. Live Update At 09:17:01 EDT: On Thursday, August 06, 2026 Iovance Biotherapeutics Inc. stock [NASDAQ: IOVA] is trending up by 32.95%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Iovance Biotherapeutics Inc. sits in classic high-growth, high-burn biotech territory, and traders in IOVA need to understand that up front. The company generated about $71.4M in total revenue last quarter, tied to the early commercialization push that includes its FDA-approved Amtagvi therapy. That sounds solid for a launch story, but the income statement shows the real picture. Iovance posted a net loss of roughly $79M for the quarter, driven by heavy research and development spend of about $62.5M and selling, general, and administrative costs near $47.5M. That kind of loss pushes key margins deep into negative territory and keeps IOVA far from traditional valuation metrics like a meaningful P/E ratio. On the balance sheet, though, IOVA has breathing room. Cash and equivalents plus short-term investments total around $313M, with a current ratio of 3.6 and very modest debt - long-term obligations near $43.9M. For traders, that means dilution risk is always on the table, but bankruptcy worries stay low near term. On the chart, IOVA has pulled back from the $5.50-$5.60 area down toward the low-$4 range in recent days, showing a choppy downtrend but with clear intraday volatility. That volatility is exactly what momentum traders watch. Why traders are watching IOVA's hiring and options grants. The latest Iovance Biotherapeutics news is simple but important: the company granted inducement stock options covering 139,930 shares to 17 new non-executive hires, all under its 2021 Inducement Plan. Every option is struck at $4.66 and vests over three years, assuming those hires stick around. That structure tells traders a lot about where IOVA management's head is. First, Iovance Biotherapeutics is not shrinking. It is still building. These are new hires added after the FDA approval and launch of Amtagvi, the company's TIL cancer therapy. When a biotech moves from the lab to the commercial stage, it needs a very different team: sales, market access, manufacturing, quality, reimbursement. IOVA tying those people to three-year options at current price levels signals it expects that build-out to matter over time. Second, the $4.66 strike price sits right in the recent trading range. The multi-day data show IOVA closing between roughly $3.93 and $5.48, with the most recent closes around $4.34-$4.36. Management is effectively saying to new talent: "You win if we grow this beyond where we are now." That's a direct, performance-linked bet. Intraday, IOVA has shown strong pre-market and early-session swings from about $4.30 up into the mid-$5s before settling. That kind of range attracts day traders who like liquidity and clear levels. The inducement grants add a narrative layer: the more Iovance Biotherapeutics scales its Amtagvi rollout, the more traders will dissect each hiring and options move as a tell on management's confidence. For short-term traders, IOVA is a volatile launch-stage biotech. For swing traders, the post-approval expansion story backed by fresh equity incentives may set up bigger trend moves if the market starts to respect future revenue growth. Conclusion. Iovance Biotherapeutics sits in that tricky zone where the science has cleared a major hurdle - FDA approval for Amtagvi - but the business still has to prove it can scale. The fresh inducement stock options for 139,930 shares spread across 17 new non-executive hires show IOVA is leaning into that challenge rather than backing off. A three-year vesting schedule at a $4.66 strike lines up talent with the long grind of turning a new therapy into a durable franchise. Financially, IOVA is running heavy quarterly losses and burning cash, but it also holds more than $200M in cash and over $300M when you include short-term investments, plus relatively low debt. That gives Iovance Biotherapeutics time to keep pushing Amtagvi and its broader TIL platform without immediate balance sheet panic. For traders, the key is respecting both sides of that coin: runway plus risk. IOVA's chart tells the rest of the story. The stock has faded off recent highs into the low-$4 range while still printing sharp intraday spikes above $5 in pre-market trading. That's exactly the kind of action where disciplined traders can thrive - if they manage risk. As Tim Sykes likes to hammer home, "Cut losses quickly, don't marry a stock, and always let the chart and price action guide you - not your hopes." As Tim Bohen, lead trainer with StocksToTrade says, "I focus on momentum that's visible right now. Speculation on future moves is outside my playbook." Taken together, those trading principles highlight why Iovance Biotherapeutics offers a live case study in that mindset for anyone trading high-volatility biotech names. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. Why top traders call it "money Monday" If you hate Mondays... That's probably because you don't know about MONEY MONDAYS. Most traders don't know this but... There's a unique kind of trade you can make every Monday morning... That often delivers more gains in 1 day than most people see in a year. Like on one recent Monday... When you could have ridden MSS for a +149% in one day. Even with a small $1,000 starting stake... that's almost $1,500 profit potential! Of course, I can't promise you future returns or against losses... But it's almost that time again. Will you join StocksToTrade, Inc.?

Yahoo Finance
Aug 6th, 2026
Iovance reports record Q2 revenue of $99M, up 66% year-over-year, with 56% gross margin

Iovance Biotherapeutics reported record second quarter 2026 revenue of approximately $99 million, up 66% year-over-year. US Amtagvi revenue reached roughly $91 million, whilst gross margin increased to 56%. The commercial biotechnology company, which develops tumour infiltrating lymphocyte therapies for cancer patients, saw total product revenue rise 39% from the first quarter. Global Proleukin revenue contributed approximately $9 million and is expected to grow throughout 2026. Research and development expenses decreased by around 6% compared to the first quarter, marking the fourth consecutive quarter of improvements. The company is reviewing its full-year 2026 revenue guidance of $350 million to $370 million based on strong second-quarter performance and demand trends, with an update expected in the third quarter. The FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas.